- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05309421
Jednoramenná studie hodnotící účinnost a bezpečnost EVX-01 v kombinaci s pembrolizumabem u dospělých s neresekovatelným nebo metastatickým melanomem
Otevřená studie s jedním ramenem hodnotící účinnost a bezpečnost EVX-01 v kombinaci s pembrolizumabem při léčbě inhibitory Checkpoint u dospělých s neresekovatelným nebo metastatickým melanomem
The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Patients will initiate treatment with pembrolizumab at the start of the trial and receive up to 18 treatment cycles (approximately 2 years). Immunization with the EVX-01 will be initiated at Week 12. In total, 10 doses of EVX-01 will be administered intramuscularly, with 6 doses given two weeks apart and 4 booster doses at later time points.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
New South Wales
-
Wollstonecraft, New South Wales, Austrálie, 2065
- Melanoma Institute Australia
-
-
Western Australia
-
Nedlands, Western Australia, Austrálie, 6009
- One Clinical Research
-
-
-
-
Italy
-
Milan, Italy, Itálie
- Divisione di Oncologia Medica del Melanoma
-
Naples, Italy, Itálie
- Instituto Nazionale Tumori IRCCS Fondazione
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Be at least 18 years of age on day of signing informed consent.
-
Histologically confirmed, and not amenable to local therapy, metastatic or unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system.
- Patient may not have a diagnosis of uveal or ocular melanoma.
- Patients must be treatment naïve to checkpoint inhibitor (CPI) therapy
- Patients must have testing for a BRAF mutation prior to study entry.
Note: Patients with BRAF V600E mutant melanoma may have received prior BRAF inhibitor therapy as first-line systemic therapy and be eligible for this study as second line treatment. At the discretion of the investigator, patients with BRAF V600E mutant melanoma who have NOT received a BRAF inhibitor are also eligible for this study as first line treatment if they meet the following additional criteria:
i. LDH < local ULN, ii. No clinically significant tumor related symptoms in the judgment of the investigator, and iii. Absence of rapidly progressing metastatic melanoma in the judgment of the investigator
- Have measurable disease per RECIST 1.1 as assessed by the local site investigator within 4 weeks prior to the first visit. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- Patients must be willing and able to provide fresh or frozen tumor tissue from an unresectable or metastatic site of disease for neoepitope and biomarker analyses. If a sufficient amount of tumor tissue from an unresectable or metastatic site is not available prior to the start of the screening phase, subjects must consent to allow the acquisition of additional tumor tissue. In addition, participants may provide additional biopsy at the time of discontinuation due to progression.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
- Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
- Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: EVX-01 in combination with pembrolizumab
EVX-01 is administered im. Pembrolizumab is administered according to label |
Investigational drug given in combination with standard of care Standard of care
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in the best overall response (BOR)
Časové okno: Measurements at Baseline through study completion (up to 102 weeks)
|
Composite of a BOR of complete response (CR) or PR for patients with SD at the time of first EVX-01 administration and a BOR of CR for patients with PR at the time of first EVX-01 administration, within 2 years of treatment with pembrolizumab, as per RECIST 1.1 criteria |
Measurements at Baseline through study completion (up to 102 weeks)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in overall response rate
Časové okno: Measurements at Baseline through study completion (up to 102 weeks)
|
Overall response rate, defined as the proportion of the patients who have best response as CR or PR assessed 2 years after initiation of treatment with pembrolizumab, as per RECIST 1.1 criteria |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Change in progression free survival (PFS)
Časové okno: Measurements at Baseline through study completion (up to 102 weeks)
|
PFS in patients with an assessment of SD, PR, or CR at the time of first EVX-01 administration, assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from the first EVX-01 administration to the first documented disease progression per RECIST 1.1. criteria or death due to any causes, whichever occurs first |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Change in overall survival (OS)
Časové okno: Measurements at Baseline through study completion (up to 102 weeks)
|
OS assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from initiation of treatment of pembrolizumab to death due to any cause |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs)
Časové okno: Measurements at Baseline through study completion (up to 102 weeks)
|
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs) |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Immunologic response induced by EVX-01
Časové okno: Measurements at Baseline through study completion (up to 102 weeks)
|
Activation and level of neoepitope specific T-cells before, during and after EVX-01 immunization |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Percentage of patients in which EVX-01 is generated, produced, and administered
Časové okno: From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)
|
Percentage of patients in which EVX-01 is generated, produced, and administered |
From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- EVX-01-001
- KEYNOTE-D36 (Jiný identifikátor: Merck Sharp & Dohme Corp.)
- 2024-512393-10-00 (Ctis)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .